Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Medtronic
Fish and Richardson
Julphar
Harvard Business School
Queensland Health
Teva
McKesson
Healthtrust

Generated: September 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,763,920

« Back to Dashboard

Title:Solid dispersions comprising tacrolimus
Abstract: A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.
Inventor(s): Holm; Per (Vanlose, DK)
Assignee: VELOXIS PHARMACEUTICALS A/S (Kobenhavn, DK)
Filing Date:Nov 06, 2015
Application Number:14/934,908
Claims:1. A solid pharmaceutical composition comprising (i) a solid carrier, and (ii) tacrolimus in a mixture of at least two hydrophilic or water-miscible vehicles having a melting point between 30.degree. C. and the melting point of tacrolimus, wherein the tacrolimus is present in the composition at a concentration of between 0.01 w/w % and 15 w/w %.

2. The solid pharmaceutical composition of claim 1, wherein the hydrophilic or water-miscible vehicles have a melting point between 40.degree. C. and the melting point of tacrolimus.

3. The solid pharmaceutical composition of claim 1, wherein the hydrophilic or water-miscible vehicles have a melting point between 50.degree. C. and the melting point of tacrolimus.

4. The solid pharmaceutical composition of claim 1, wherein one hydrophilic or water-miscible vehicle is a poloxamer.

5. The solid pharmaceutical composition of claim 4, wherein the poloxamer is poloxamer 188.

6. The solid pharmaceutical composition of claim 1, wherein one hydrophilic or water-miscible vehicle is polyethylene glycol.

7. The solid pharmaceutical composition of claim 6, wherein the polyethylene glycol has an average molecular weight of at least 1500.

8. The solid pharmaceutical composition of claim 1, wherein the composition further comprises a release-modifying agent.

9. The solid pharmaceutical composition of claim 8, wherein the composition provides a W.sub.50 (the time where the plasma concentration is 50% or more of C.sub.max) of at least 12 hours.

10. The solid pharmaceutical composition of claim 9, wherein the composition provides a W.sub.50 (the time where the plasma concentration is 50% or more of C.sub.max) of at least 14 hours.

11. A solid pharmaceutical composition comprising agglomerated particles comprising a solid carrier and tacrolimus dispersed or dissolved in a mixture of at least two hydrophilic or water-miscible vehicles having a melting point between 30.degree. C. and the melting point of tacrolimus, wherein (i) the tacrolimus is present in the composition at a concentration of between about 0.01 w/w % and about 15 w/w %, and (ii) the particles have a geometric weight mean diameter d.sub.gw of from 100 to 1000 .mu.m.

12. The solid pharmaceutical composition of claim 11, wherein the hydrophilic or water-miscible vehicles have a melting point between 40.degree. C. and the melting point of tacrolimus.

13. The solid pharmaceutical composition of claim 11, wherein the hydrophilic or water-miscible vehicles have a melting point between 50.degree. C. and the melting point of tacrolimus.

14. The solid pharmaceutical composition of claim 11, wherein one hydrophilic or water-miscible vehicle is a poloxamer.

15. The solid pharmaceutical composition of claim 14, wherein the poloxamer is poloxamer 188.

16. The solid pharmaceutical composition of claim 11, wherein one hydrophilic or water-miscible vehicle is polyethylene glycol.

17. The solid pharmaceutical composition of claim 16, wherein the polyethylene glycol has an average molecular weight of at least 1500.

18. The solid pharmaceutical composition of claim 11, wherein the composition further comprises a release-modifying agent.

19. The solid pharmaceutical composition of claim 18, wherein the composition provides a W.sub.50 (the time where the plasma concentration is 50% or more of C.sub.max) of at least 12 hours.

20. The solid pharmaceutical composition of claim 19, wherein the composition provides a W.sub.50 (the time where the plasma concentration is 50% or more of C.sub.max) of at least 14 hours.

21. A solid pharmaceutical composition prepared by a process comprising the steps of: (a) spraying a solid carrier with tacrolimus dispersed or dissolved in a melted mixture of two hydrophilic or water-miscible vehicles, the vehicles having a melting point between 30.degree. C. and the melting point of tacrolimus, (b) mechanically working the product from step (a) to form agglomerated particles having a geometric weight mean diameter d.sub.gw of from 100 to 1000 .mu.m, and (c) compressing the agglomerated particles, wherein the tacrolimus is present in the composition at a concentration of between about 0.01 w/w % and about 15 w/w %.

22. The solid pharmaceutical composition of claim 21, wherein the hydrophilic or water-miscible vehicles have a melting point between 40.degree. C. and the melting point of tacrolimus.

23. The solid pharmaceutical composition of claim 21, wherein the hydrophilic or water-miscible vehicles have a melting point between 50.degree. C. and the melting point of tacrolimus.

24. The solid pharmaceutical composition of claim 21, wherein one hydrophilic or water-miscible vehicle is a poloxamer.

25. The solid pharmaceutical composition of claim 24, wherein the poloxamer is poloxamer 188.

26. The solid pharmaceutical composition of claim 21, wherein one hydrophilic or water-miscible vehicle is polyethylene glycol.

27. The solid pharmaceutical composition of claim 26, wherein the polyethylene glycol has an average molecular weight of at least 1500.

28. The solid pharmaceutical composition of claim 21, wherein the composition further comprises a release-modifying agent.

29. The solid pharmaceutical composition of claim 28, wherein the composition provides a W.sub.50 (the time where the plasma concentration is 50% or more of C.sub.max) of at least 12 hours.

30. The solid pharmaceutical composition of claim 29, wherein the composition provides a W.sub.50 (the time where the plasma concentration is 50% or more of C.sub.max) of at least 14 hours.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Dow
Harvard Business School
US Department of Justice
Cerilliant
Healthtrust
Johnson and Johnson
Argus Health
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.